Associate
Chartered Patent Attorney
European Patent Attorney
UK Design Attorney
Postgraduate Certificate in Intellectual Property Law, Queen Mary University of London
BSc Biochemistry, University College London
MSc Cellular Therapy from Bench to Market, King’s College London
Thank you
Matt graduated from UCL in 2017 with a bachelor’s degree in Biochemistry. He subsequently obtained a master’s degree entitled ‘Cellular Therapy from Bench to Market’, a program which blended biology and business to explore the science, regulation and routes to market underpinning advanced therapies. His thesis was a business plan to commercialise a stem cell-derived therapy for Parkinson’s disease. Following this, Matt joined the Cell and Gene Therapy Catapult as a laboratory technician gaining experience in ddPCR, cell culture, non-viral gene editing techniques, flow cytometry, as well as upstream and downstream processing of AAV (viral vector) for gene therapy applications
Matt joined Keltie in 2022 following three years training at another leading patent law firm. He qualified as a UK and European Patent Attorney in 2024.
Matt particularly enjoys working closely with clients to understand not only the detail behind their technology, but the business needs behind their intellectual property. He has experience in both drafting and prosecution, advising multinational pharmaceutical clients and early-stage spin-outs in a range of fields including antibodies, cell and gene therapies, non-viral gene editing, MedTech, small molecules, and nanotechnologies.
02.04.2024
Patents, plausibility and data: one year on from G 2/21On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.
19.08.2021
Dual filing, cloned rights and new guidelines: Brexit’s impact on Trade Marks, Designs and IP ManagementBritain leaving the European Union has changed how Trade Marks and Design Rights are filed and managed. According to Kane Ridley, Keltie’s Head of Trade Mark Support, now is the time for everyone to review their IP portfolios to avoid lost UK rights and future complications.
06.06.2022
How do I go about getting a patent?15.05.2023
Jonathan Goodacre promoted to Partner10.01.2022
Pharmaceutical trade marks - top tipsOtherLess related knowledge
Thank you